Posters
« Back
Identification and Quantitation of Mixture Components of Formulated Products by NMR
EP23985
Identification and Quantitation of Mixture Components of Formulated Products by NMR
Submitted on 25 Apr 2016

Brent G. Pautler, Patrick Wheeler, Sergey Golotvin, Rostislav Pol, Joe DiMartino
Advanced Chemistry Development, Inc. (ACD/Labs), 8 King Street East, Suite 107, Toronto, ON Canada, M5C 1B5
Poster Views: 863
View poster »
Poster Abstract
It has become increasingly important for chemists and analysts to be able to test and determine the various components that may be present in mixtures, both qualitatively and quantitatively, to solve a wide variety of scientific problems. NMR spectroscopy has emerged as a powerful, non-destructive analytical technique that provides unique information that may not be readily accessible by other means to support the needs of various industries, including polymers, pharmaceuticals, consumer products, and nutrition, to name a few.

[1] Simpson et al., J. Chem. Edu. 2009, 86, 360. [2] Wuet al., J. Magn. Reson. A 1995, 115, 123.Report abuse »
Questions
Ask the author a question about this poster.
Ask a Question »

Creative Commons

Related Posters


MODEL-AD: Bioinformatics and Data ManagementMODEL-AD: Bioinformatics and Data Management
Bruce Lamb1, Michael Sasner2, Andrew Saykin1, Lara Mangravite3, Gregory Carter2

MODEL-AD: The Disease Modeling Project
M.Sasner1, A. Oblak2, H. Williams1, G. Howell1, B.T. Lamb2 and the MODEL-AD consortium

MODEL-AD: Genetic models of late-onset Alzheimer’s disease
*A. OBLAK1,2, G. CARTER3, G. R. HOWELL3, B. LOGSDON4, L. MANGRAVITE4, K. NHO2, L. OMBERG4, K. D. ONOS3, V. PHILIP3, C. PREUSS3, S. J. SUKOFF RIZZO3, M. SASNER3, L. SHEN1,2, A. J. SAYKIN1,2, P. TERRITO1,2, A. UYAR3, H. WILLIAMS3, B. T. LAMB1,5

ESTUDIO ANALÍTICO DE LA CALIDAD Y VALORACION NUTRICIONAL DE LALECHE HUMANA DE LAS MADRES DONANTES EN LA ZONA NORTE DEL TOLIMA
Kevin Fernando Romero Acosta; Monica Patricia Osorio Tangarife; Guillermo Salamanca Grosso

Preclinical drug screening in new generation Alzheimer’s disease mouse models: The MODEL-AD Consortium Strategy
P.R. Territo1, S.J. Sukoff Rizzo2, K. Onos2, J.A. Meyer1, J. Peters1, S.C. Persohn1, B.R. McCarthy1, A.A. Riley1, S. Quinney1, D. Jones1, M. Sasner2, G. Howell2, H. Williams2, A.J. Oblak1, B.L. Lamb1 and the MODEL-AD consortium